Get the Stockscreener App
6.61
7.68%
-0.55
After Hours:
6.50
-0.11
-1.66%
Silence Therapeutics Plc Adr stock is traded at $6.61, with a volume of 212.78K.
It is down -7.68% in the last 24 hours and up +32.20% over the past month.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
See More
Previous Close:
$7.16
Open:
$7.17
24h Volume:
212.78K
Relative Volume:
2.09
Market Cap:
$197.83M
Revenue:
$31.37M
Net Income/Loss:
$-53.77M
P/E Ratio:
-4.547
EPS:
-1.4537
Net Cash Flow:
$-49.02M
1W Performance:
-7.42%
1M Performance:
+32.20%
6M Performance:
+68.19%
1Y Performance:
-62.61%
1-Day Range:
$6.3812
$7.34
1-Week Range:
$6.3812
$7.4952
52-Week Range:
$1.97
$18.29
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Name
Silence Therapeutics Plc Adr
Sector
Industry
Phone
44-0-20-3457 6900
Address
72 HAMMERSMITH ROAD, LONDON
Compare SLN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
6.61 | 338.20M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Goldman | Sell |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Stock (SLN) Latest News
Silence Therapeutics (NASDAQ:SLN) Stock Price Down 2.1%Time to Sell? - MarketBeat
5 Under-the-Radar Biotech Stocks That Could Soar in 2026 - Barchart.com
Silence Therapeutics completes enrollment in PV treatment study - Investing.com
Check Out Insider Trades For Silence Therapeutics Plc ADR (SLN) Stock - fostersleader.com
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Average Price Target from Analysts - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
GAMMA Investing LLC Buys 4,773 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Goldman Sachs Group Inc. Sells 12,510 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $32.60 Consensus Target Price from Analysts - Defense World
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire Inc.
Silence Therapeutics (OTCMKTS:SLNCF) Shares Down 5% – Here’s What Happened - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics director Michael Davidson resigns from board - Investing.com
Silence Therapeutics director Michael Davidson resigns from board By Investing.com - Investing.com India
William Blair Issues Pessimistic Forecast for SLN Earnings - Defense World
Silence Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com South Africa
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $33.83 Average PT from Analysts - Defense World
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade - Yahoo.co
Stephens Inc. AR Invests $260,000 in Evergy Inc. (NASDAQ:EVRG) - Defense World
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Price Up 20.7% – Still a Buy? - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus - Nasdaq
Silence Therapeutics soars 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
H.C. Wainwright reiterates buy rating on Silence Therapeutics stock By Investing.com - Investing.com South Africa
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year By Investing.com - Investing.com India
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Zacks Investment Research
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Silence Therapeutics stock holds Buy rating on positive trial results By Investing.com - Investing.com UK
Silence Therapeutics director Alistair Gray retires - Investing.com
Zerlasiran shows promise in lowering cardiovascular risk - Investing.com
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Nasdaq
Silence Therapeutics to Join Guggenheim Biotech Conference By Investing.com - Investing.com South Africa
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy - Yahoo Finance
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - Nasdaq
Wall Street Analysts Predict a 361.54% Upside in Silence Therapeutics PLC Sponsored ADR (SLN): Here's What You Should Know - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? - Nasdaq
SLNCF Stock Price and Chart — OTC:SLNCF - TradingView
Claire Keast-Butler - Cooley
Our approach to nucleotide-based therapeutics - AstraZeneca
Silence Therapeutics Plc Adr Stock (SLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):